Biotech IPOs, Longevity, and China
Kilder
- Endpoints: City Therapeutics lands $200M IPO as it builds an Alnylam 2.0 in RNAi field
- BioPharma Dive: Iambic CEO on taking an AI drug company public
- BioPharma Dive: Next-gen RNAi drugmaker City prices $200M IPO - BioPharma Dive
- STAT: Hospitals’ next lucrative bet — longevity clinics
- Finance: Sarah Todd: Hospital Longevity Clinics Sell Time and Attention, Not Proven Medicine - BigGo Finance
- Endpoints: China pursues export ban on some biotech platforms
- Endpoints: Ex-Genentech scientist joins Ira Mellman at Medici; Intellia poaches CMO from Scholar Rock
- GEN: Designing the Ecosystem for CGT Success
- GEN: Danaher, Nvidia Combine Lab Instrumentation and AI to Advance Autonomous Science - Genetic Engineering and Biotechnology News
- GEN: ADC Developmentfrom Concept to Clinic - Genetic Engineering and Biotechnology News
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.